ATN-161 is a novel peptide antagonist of integrin α5β1. ATN-161 selectively binds to and blocks the receptor for integrin α5β1, thereby preventing integrin alpha5beta1 binding. This receptor blockade may result in inhibition of endothelial cell-cell interactions, endothelial cell-matrix interactions, angiogenesis, and tumor progression. It has potential antineoplastic activity.
CAT# | R0965 |
CAS | 262438-43-7 |
Synonyms/Alias | ATN161; ATN 161; ATN-161; AcPHSCNNH2 |
M.F/Formula | C23H35N9O8S |
M.W/Mr. | 597.65 |
Sequence | Ac-PHSCN-NH2 |
Labeling Target | Integrin α5β1 |
Appearance | white solid powder |
Purity | >98% (or refer to the Certificate of Analysis) |
Activity | Antagonist |
Areas of Interest | Cancer |
* Please kindly note that our products and services can only be used to support research purposes (Not for clinical use).
Creative Peptides has accumulated a huge library of peptide knowledge including frontier peptide articles, application of peptides, useful tools, and more!
KAI-1678, a synthetic 21-amino acid, is a novel PKC-epsilon (ε-PKC) inhibitor with a molecular weight of 2541 Da ...
Dulaglutide, sold under the brand name Trulicity, is a GLP-1 receptor agonist which is a class of medications th ...
Icatibant, sold under the trade name Firazyr, is a plasma kallikrein inhibitor and the bradykinin B2 receptor an ...
In the respiratory tract, there are tachykinin P (SP) and neurokinin A (NKA) in capsaicin-sensitive primary affe ...
Long-term potentiation (LTP) is a persistent synaptic enhancement which is thought to be a substrate for memory. ...